1-叔丁基-3-[2-(环己基氨基)-5-硝基苯基]磺酰基脲

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-叔丁基-3-[2-(环己基氨基)-5-硝基苯基]磺酰基脲
• 中文别名: 1-(3,4-二羟基-5-硝基苯基)-2-苯基-1-乙酮
• 英文名称: BM 531
• 英文别名: N-tert-butyl-N'-(2-cyclohexylamino-5-nitrobenzenesulfonyl)urea；N-[(2-cyclohexylamino-5-nitrobenzene)sulfonyl]N'-tert-butyl urea；N'-tert-butyl-N-[2-(cyclohexylazaniumyl)-5-nitrophenyl]sulfonylcarbamimidate
• 化学式: C₁₇H₂₆N₄O₅S
• 分子量: 398.483
• InChiKey: LBAPYVMLNHDSLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  142
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• DIAGNOSIS AND TREATMENT OF ASPIRIN-EXACERBATED RESPIRATORY DISEASE (AERD)
  申请人：BRIGHAM AND WOMEN'S HOSPITAL, INC.

  公开号：US20150253327A1

  公开（公告）日：2015-09-10

  Described herein are assays and methods relating to the diagnosis, prognosis, and treatment of aspirin-exacerbated respiratory disease (AERD) by detecting and/or measuring the level of platelet-bound leukocytes in a subject or a sample obtained from a subject.

  本文描述了一种检测和/或测量受试者或从受试者获取的样本中血小板结合白细胞水平的测定和方法，用于诊断、预后和治疗阿司匹林加重的呼吸道疾病（AERD）。
• DERIVES DE SULFONAMIDES BENZENIQUES ET LEURS UTILISATIONS
  申请人：Université de Liège

  公开号：EP1140810B1

  公开（公告）日：2004-03-17
• TREATMENT OF RESPIRATORY DISORDERS WITH ARACHIDONATE15-LIPOXYGENASE (ALOX15) INHIBITORS
  申请人：Regeneron Pharmaceuticals, Inc.

  公开号：EP3902567A2

  公开（公告）日：2021-11-03
• USE OF TP MODULATORS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS IN ASPIRIN SENSITIVE AND OTHER POPULATIONS
  申请人：Phillips David R.

  公开号：US20090012115A1

  公开（公告）日：2009-01-08

  The present invention provides methods and compositions useful in the treatment or prevention of cardiovascular disorders in individuals for whom therapy with a COX-1 enzyme inhibitor is not feasible due to sensitivity, intolerance, or resistance to the inhibitor. Additionally, the invention provides methods of treating cardiovascular disorders in an individual who is receiving a therapeutically effective dose of a TP modulator and is instructed or advised to avoid and/or not to take aspirin or another COX-1 inhibitor.
• Treatment Of Respiratory Disorders With Arachidonate 15-Lipoxygenase (ALOX15) Inhibitors
  申请人：Regeneron Pharmaceuticals, Inc.

  公开号：US20200254070A1

  公开（公告）日：2020-08-13

  The present disclosure provides methods of treating patients having a respiratory disorder, methods of identifying subjects having an increased risk of developing a respiratory disorder, and methods of detecting human Arachidonate 15-Lipoxygenase (ALOX15) variant nucleic acid molecules and variant polypeptides.